Altimmune (NASDAQ:ALT) Now Covered by Analysts at Truist Financial

Equities research analysts at Truist Financial started coverage on shares of Altimmune (NASDAQ:ALT) in a research report issued to clients and investors on Wednesday. The brokerage set a “buy” rating and a $12.00 price target on the stock. Truist Financial’s price target suggests a potential upside of 250.88% from the stock’s previous close.

A number of other equities analysts also recently issued reports on the company. HC Wainwright increased their price target on Altimmune from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday. Barclays assumed coverage on shares of Altimmune in a research note on Tuesday, January 27th. They issued an “overweight” rating and a $20.00 price objective for the company. Wall Street Zen cut shares of Altimmune from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. B. Riley Financial cut their target price on shares of Altimmune from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Friday, March 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Altimmune in a report on Monday, December 29th. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, Altimmune currently has an average rating of “Moderate Buy” and a consensus target price of $18.00.

Altimmune Trading Down 3.1%

NASDAQ ALT traded down $0.11 on Wednesday, hitting $3.42. 3,409,766 shares of the stock were exchanged, compared to its average volume of 4,610,255. The company has a debt-to-equity ratio of 0.15, a quick ratio of 18.55 and a current ratio of 18.55. Altimmune has a 52-week low of $2.90 and a 52-week high of $7.73. The firm has a market capitalization of $444.84 million, a P/E ratio of -3.39 and a beta of 0.13. The stock has a fifty day moving average price of $4.48 and a two-hundred day moving average price of $4.29.

Altimmune (NASDAQ:ALT) last announced its earnings results on Thursday, March 5th. The company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.02). Altimmune had a negative net margin of 214,860.98% and a negative return on equity of 49.35%. The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $0.00 million. Research analysts forecast that Altimmune will post -1.35 EPS for the current fiscal year.

Insider Transactions at Altimmune

In related news, CEO Jerome Benedict Durso bought 20,000 shares of the business’s stock in a transaction on Friday, March 6th. The shares were bought at an average price of $3.54 per share, for a total transaction of $70,800.00. Following the completion of the purchase, the chief executive officer directly owned 32,500 shares of the company’s stock, valued at approximately $115,050. This trade represents a 160.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director John Gill bought 12,500 shares of Altimmune stock in a transaction on Tuesday, December 23rd. The stock was purchased at an average price of $4.10 per share, with a total value of $51,250.00. Following the completion of the acquisition, the director directly owned 12,500 shares of the company’s stock, valued at $51,250. This represents a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have purchased 55,527 shares of company stock worth $213,778. 4.40% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ALT. Two Sigma Investments LP increased its stake in Altimmune by 356.6% during the 3rd quarter. Two Sigma Investments LP now owns 1,996,848 shares of the company’s stock valued at $7,528,000 after purchasing an additional 1,559,562 shares in the last quarter. State Street Corp lifted its stake in shares of Altimmune by 42.2% during the fourth quarter. State Street Corp now owns 5,119,703 shares of the company’s stock worth $18,482,000 after buying an additional 1,518,448 shares during the period. Vanguard Group Inc. grew its holdings in shares of Altimmune by 23.3% during the third quarter. Vanguard Group Inc. now owns 6,373,638 shares of the company’s stock valued at $24,029,000 after buying an additional 1,206,514 shares during the last quarter. Nuveen LLC increased its position in shares of Altimmune by 514.9% in the 4th quarter. Nuveen LLC now owns 1,244,211 shares of the company’s stock valued at $4,492,000 after acquiring an additional 1,041,856 shares during the period. Finally, Marshall Wace LLP acquired a new position in shares of Altimmune in the 4th quarter valued at $3,331,000. Institutional investors own 78.05% of the company’s stock.

Key Headlines Impacting Altimmune

Here are the key news stories impacting Altimmune this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $25 price target, signaling continued analyst confidence in Altimmune’s upside potential. MarketBeat ALT
• Positive Sentiment: The firm raised several near-term EPS forecasts (Q1–Q4 2026 and parts of 2026–2027, plus an improved FY2026 and FY2027 view), which investors often view as a sign of improving near-term execution or lower expected cash burn. MarketBeat ALT
• Positive Sentiment: Media coverage highlighted HC Wainwright’s bullish stance and $25 target, which can attract momentum buyers despite weakness elsewhere. Altimmune Stock Price Expected to Rise
• Neutral Sentiment: Market data shows reported short interest numbers of “0 shares” and NaN changes — likely a reporting/data anomaly, so short‑interest signals are not informative today. MarketBeat ALT
• Neutral Sentiment: Consensus remains that Altimmune will be unprofitable for the current year (consensus ~($1.35) EPS), so analyst optimism is relative to an ongoing loss profile. MarketBeat ALT
• Negative Sentiment: HC Wainwright cut its FY2028 and FY2029 EPS forecasts materially (FY2028 to about ($1.19) and FY2029 to about ($0.79)), weakening the long‑term earnings outlook and suggesting more cautious assumptions on product timing or commercialization. MarketBeat ALT
• Negative Sentiment: Altimmune reported a recent quarterly EPS miss and remains unprofitable with negative margins, which keeps execution and cash‑flow risk in focus for investors. MarketBeat ALT

Altimmune Company Profile

Altimmune, Inc is a clinical-stage biopharmaceutical company headquartered in Gaithersburg, Maryland, dedicated to the development of vaccines and immunotherapeutics. The company leverages proprietary technology platforms to create intranasal vaccine candidates and novel therapies targeting liver diseases and metabolic disorders. Altimmune’s approach emphasizes the stimulation of both systemic and mucosal immune responses to address unmet medical needs in infectious and chronic conditions.

Among its lead programs, NasoVAX is an investigational intranasal influenza vaccine designed to provide broad, long-lasting protection through a single, non-invasive dose.